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Discovery of a Novel Polymer for Xeno-Free, Long-Term
Culture of Human Pluripotent Stem Cell Expansion
Aishah Nasir, Jordan Thorpe, Laurence Burroughs, Joris Meurs, Sara Pijuan-Galito,
Derek J. Irvine, Morgan R. Alexander,* and Chris Denning*
Human pluripotent stem cells (hPSCs) can be expanded and differentiated in
vitro into almost any adult tissue cell type, and thus have great potential as a
source for cell therapies with biomedical application. In this study, a
fully-defined polymer synthetic substrate is identified for hPSC culture in
completely defined, xenogenic (xeno)-free conditions. This system can
overcome the cost, scalability, and reproducibility limitations of current hPSC
culture strategies, and facilitate large-scale production. A high-throughput,
multi-generational polymer microarray platform approach is used to test over
600 unique polymers and rapidly assess hPSC-polymer interactions in
combination with the fully defined xeno-free medium, Essential 8 (E8). This
study identifies a novel nanoscale phase separated blend of
poly(tricyclodecane-dimethanol diacrylate) and poly(butyl acrylate) (2:1 v/v),
which supports long-term expansion of hPSCs and can be readily coated onto
standard cultureware. Analysis of cell-polymer interface interactions through
mass spectrometry and integrin blocking studies provides novel mechanistic
insight into the role of the E8 proteins in promoting integrin-mediated hPSC
attachment and maintaining hPSC signaling, including ability to undergo
multi-lineage differentiation. This study therefore identifies a novel substrate
for long-term serial passaging of hPSCs in serum-free, commercial
chemically-defined E8, which provides a promising and economic hPSC
expansion platform for clinical-scale application.
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To improve application of adherent hu-
man pluripotent stem cell (hPSC) culture,
there has been a shift from the use of
animal-derived feeder layers and poorly de-
fined media to systems using surfaces and
culture media that are fully-defined.[1–19]
Several commonly utilized feeder-free
hPSC culture systems used with defined
media formulations still rely on a broad
range of proteins, lipids, small molecules,
matrix proteins (e.g. Matrigel, vitronectin,
laminin, and fibronectin), or peptide
containing surfaces (e.g. Synthemax and
PuraMatrix) to promote hPSC culture.
Minimizing or eliminating the use of such
biological reagents would help to overcome
batch-batch variability during cell process-
ing and reduce costs, which limit large-scale
production (estimated at $10 000-$15 000
for 1 billion hPSCs required for a single
patient intervention).[20]
Use of polymers as culture substrates
whilst safe and cost-effective solutions iden-
tified by us and others have been lim-
ited by their dependence on xenogenic
(xeno) components from culture medium
(e.g. bovine serum albumin containing
commercial defined mTESR1 and StemPro) for maintaining
hPSC culture.[21–25] In the following study, we used high-
throughput microarray screening strategies (previously used by
us and others) to identify novel materials capable of support-
ing hPSCs in a culture system simplified by using the xeno-free,
commercial, chemically-defined Essential 8 (E8) medium.[26–29]
Subsequent characterization of cell interactions with the scaled
up synthetic polymer revealed the underlying mechanisms gov-
erning cellular response without the contribution of xenogenic
components.
Using a multigenerational polymer microarray screening ap-
proach, the first generation array consisted of 284 chemically di-
verse monomers (photo-curable and readily commercially avail-
able) pin-printed and UV polymerized onto poly(2-hydroxyethyl
methacrylate) (polyHEMA) coated slides as spots in triplicate
(Figure 1a, monomer structures presented in Figure S1, Sup-
porting Information with monomer names in Table S1, Support-
ing Information).[21,30] ReBl-PAT cells, a human induced pluripo-
tent stem cell (hiPSC) line generated in-house,[31] were seeded
onto arrays in E8 for 24 h before quantification of cell attach-
ment and response using automated fluorescence microscopy.
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Figure 1. Multi-generation microarray screen of polymeric substrates a) A first-generation array of 284 chemically diverse monomers were screened for
hPSC attachment with ReBl-PAT hiPSCs in E8 medium for 24 h. b) Arrays were then fixed and stained for pluripotent marker OCT4, imaged using Imstar
automated fluorescence microscopy and OCT4+ nuclei and total nuclei counts assessed with Cell-Profiler. Representative image shows a polymer spot
(n) supporting high hPSC attachment. c) Attachment on materials is ranked by OCT4+ nuclei count plotted against total cell number (DAPI). Nineteen
materials selected for second-generation co-polymer screening (highlighted in red). Each point represents mean (n = 9) and SEM for OCT4 count. d) A
total of 361 chemistries screened for 24 h included 19 selected monomers printed alone and mixed pairwise (2:1 v/v). e) OCT4+ hPSC attachment (n = 9)
was clustered by Euclidean distance measure (intensity scale represents OCT4+ nuclei count) and f) ranked (high to low) (full list in Table S3, Supporting
Information). Polymer D, (TCDMDA) containing polymers are denoted in red. All letter IDs mentioned are defined in Figure S3, Supporting Information.
Materials were ranked by total number of nuclei for cell at-
tachment gauged by DAPI staining (Figure S2a,b Supporting
Information, see rank order with polymer names Table S2,
Supporting Information), or by number of OCT4+ cells as a
marker of pluripotency (Figure S2c, Supporting Information, see
rank order with polymer names Table S2, Supporting Informa-
tion), and the two parameters were plotted against each other
(Figure 1b,c).
From this initial screen, nineteen monomers were selected
for a second-generation co-polymer screen (denoted in Fig-
ure 1c as red letter IDs, and corresponding polymer structure
shown in Figure S3, Supporting Information). Monomers resid-
ing on the y = x line show OCT4 expression in >80% hPSCs,
whereas those shifted below the line show decreasing percent-
age of pluripotency either from loss of expression or attachment
of non-viable debris cells. All selected polymers cover a large
chemical diversity, show high percentages of OCT4 expression
(>80%), but a varied level of attachment. Examples of materi-
als taken forward to the second screen include high attachment,
monomer P (tetrahydrofurfuryl acrylate, THFuA; ≈55 ± 35 cells
spot−1, 93% OCT4 expression) to low attachment monomer S (N-
(hydroxymethyl)acrylamide, HMAm; ≈1 ± 2 cells spot−1, 100%
OCT4 expression). This panel of candidates provided a variety
of polymer combinations to be assessed in a second generation
screen, where homopolymers were included alone and mixed
pairwise as 2:1 v/v (where each monomer was combined as a ma-
jor and minor component) prior to printing to create a library of
361 chemistries printed in triplicate (Figure 1d).
Screening 361 co-polymers by OCT4+ ReBl-PAT attachment
at 24 h gave a z factor ≈ 0.5,[32] indicating good assay suitabil-
ity was calculated from ReBl-PAT attachment to Matrigel (posi-
tive sample; mean = 125 and SD = 18) and polyHEMA (nega-
tive control, used for array slide background coating; mean = 5
and SD = 4). Clustering using Euclidean measure distance (Fig-
ure 1e) and ranking by (Figure 1f, see Table S3, Supporting In-
formation for polymer names) identified almost 80 chemistries
which supported high hPSC attachment (mean cell number > 75
cells spot−1, > 90% OCT4+ cells). More than 25% of these poly-
mers contained monomer D, tricylodecane-dimethanol diacry-
late (TCDMDA) as a homopolymer and co-polymer (combined
pairwise as either a major or minor component) (Figure 1f). TCD-
MDA also supported attachment to human dental pulp-derived
stem cells in previous microarray screening studies as both a ho-
mopolymer and co-polymer.[28]
To refine the candidate list further, the synergy ratio (SR)
of co-polymer combinations was assessed; a concept we have
previously defined where cell response to the co-polymer is
compared to individual responses of their monomer coun-
terparts (microarray screening and data acquisition methods,
Supporting Information).[27,33] While most (≈70%) of the 342
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Figure 2. Screening of co-polymer candidates at scale-up. a) ReBl-PAT hPSCs were cultured in E8 on polymers coated on 96 well plates (n = 9/condition).
Attachment was assessed at 24 and 72 h time-points and Matrigel was included as a positive control (highlighted in red). All images (5 fields of view per
well) were captured (Operetta, Perkin Elmer) and processed using Harmony image analysis software (Perkin Elmer). Cell attachment (cell coverage and
mean colony sizes) at 24 h was quantified from brightfield live-cell images processed using scripts developed with PhenoLOGIC machine learning (script
training (left center panel) training: green dots = cells, red dots background, resultant overlays (left bottom panel)) to create a mask for cell coverage
per well. At 72 h, hPSCs were fixed and stained for OCT4 expression. OCT4+ nuclei were quantified from fluorescence images (script right panel). b)
Representative brightfield images of ReBl-PATs cultured on polymers (structures to letter IDs in Table S1, Supporting Information) and Matrigel in E8
medium after 24 h. hPSC attachment on co-polymers are ranked by mean cell coverage/well quantified in c) relative to Matrigel control. (n = 9) Co-
polymer array screen ranking denoted in brackets above each bar was taken from total observed (total nuclei count) attachment (Table S3, Supporting
Information). d) Mean colony sizes (tightly packed cells with defined outer border) were calculated per field of view (n = 15 per condition). Bar graphs
represent averaged colony sizes (n) of matrigel (164), P (57), D:Q (54), B:L (53), E:M (54), H:N (47), D:F (53), and B:P (62). One way ANOVA followed by
Tukey’s multiple comparison tests (*p < 0.05,****p < 0.0001) were performed. Statistical differences denoted with red asterisks represent comparisons
between polymers and Matrigel. Remaining comparisons are labeled. e) Representative images and f) OCT4+ cell attachment per well (n) on polymers
at 72 h (≈90% OCT4 expression per well). One-way ANOVA followed by Tukey’s multiple comparison tests (*p < 0.05) (n = 9). All graphs represent
mean (±SEM). Scale bars = 200 µm.
combinations were antagonistic or merely additive (SR ≤ 1),
≈30% of the co-polymer features were determined to be synergis-
tic (SR > 1) (Figure S4a,b, Supporting Information). Consistent
with previous studies, synergistic combinations were often re-
lated to co-polymers that combined a high attachment monomer
with a low attachment monomer. Candidates taken forward for
scale-up were chosen on the basis of high cell attachment scores
(at 24 and 48 h time points; Figure 2; Figure S5, Supporting In-
formation), and consideration of synergistic performance.
The microarray assays evaluated attachment and retention
of pluripotency for 24 h, so our next experiments focused on
periods up to 72 h as an indicator of compatibility for longer
term expansion in tissue culture plastic (TCP) well-plates (de-
scribed in Figure 2a, see Supporting Information for methods).
Eleven chemistries (mixed 2:1 v/v) taken forward for scale-up
experiments, included high attachment (D:O, D:Q, B:L, H:N,
D:F, P, and B:O ranked 1–74 by total nuclei count; Table S3,
Supporting Information) and low attachment (E:M, B:P, K:A,
and L:M ranked below 100 by nuclei count; Table S3, Support-
ing Information) candidates (Figure S5, Supporting Informa-
tion). In this 96 well plate format, four chemistries failed to sup-
port initial attachment at 24 h: D:O, B:O, L:M, and K:A, likely
due to the dissolvability of polymers with isopropyl alcohol sol-
vent during coating (see production of polymer coated 6-well
plates methods, Supporting Information), which was selected
for its compatibility on TCP. Four further chemistries failed
to maintain attachment at 72 h: P, H:N, B:P, and E:M despite
showing attachment at 24 h. (Figure S6, Supporting Informa-
tion). Whilst three chemistries (D:Q, D:F, and B:L) were able
to support hPSC attachment and OCT4 pluripotency at 24 (Fig-
ure 2b–d) and 72 h (Figure 2e–f) time points at scale-up were
also high attachment candidates (from co-polymer array screen).
From the three chemistries, co-polymer D:Q was able to sup-
port high attachment of hPSCs that was most comparable with
Matrigel controls, and was thus selected for long-term scale-up
experiments.
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Figure 3. Characterization of poly(TCDMDA-blend-BA) surface. Atomic force microscopy a) Derjaguin-Muller-Toporov (DMT) modulus and b) deforma-
tion micrographs of poly(TCDMDA-blend-BA) surface coated on poly(styrene) six well plates showing a nanoscale blend of polyBA (≈50nm islands of
minor component, 30% v/v) in polyTCDMDA (background, major component, 70% v/v). c) Representative brightfield images of ReBl-PAT attachment
and maintenance at 24 and 72 h of culture. d) Growth curves of hESC: HUES7 and hiPSC: AT1 and ReBl-PAT lines on poly(TCDMDA-blend-BA) and Ma-
trigel presented as cumulative doubling time ([duration of culture x log2] / [log10 (final cell concentration/initial cell concentration)]). e) LESA-MS/MS
quantification of adsorbed proteins: FGF2, TGF𝛽1, insulin, and transferrin from E8 medium on polymer surface after 1 h of incubation (N = 3). Bar
graph represents ±SEM. One-way Anova statistical tests were performed and compared between chemistries for each protein (*p < 0.05). f) Blocking of
integrins and RGD-blocking peptides (see Table S4, Supporting Information for details) for 24 h on poly(TCDMDA-blend-BA) in E8. Bar graphs presented
as mean and error bars represent ±STDEV. (N = 3, n = 3). One way ANOVA followed by Tukey’s multiple comparison tests (*p < 0.05, **p < 0.01, ****p
< 0.0001) were performed. Statistical differences denoted with black asterisks represent comparisons between polymers and Matrigel unless indicated
otherwise. g) Phosphokinase array blots were quantified using Image Studio Software for HUES7 (N = 2, n = 4) and AT1 (N = 1, n = 2). Heatmap rep-
resents total intensity values per phosphorylated kinase normalized to background intensity and HSP60 internal control. Graph shows Mean + STDEV.
h) Schematic to summarize identified hPSC and poly(TCDMDA-blend-BA) interactions. The upper panel is zoomed in single cell-polymer interactions
from lower image showing hPSC colonies attached on a well of cultureware coated with poly(TCDMDA-blend-BA). In brief (left to right), adsorption of E8
proteins mediate initial phase of cell attachment (phase I) followed by integrin engagement (phase II) which subsequently promote key hPSC signaling
pathways (phase III).
Co-polymer D:Q, which comprises of TCDMDA mixed with
butyl acrylate (BA) (2:1 v/v) was applied to 6-well TCP plates of
≈10 cm2 base surface area per well (see Supporting Information
for methods). Surface characterization by TOFSIMS after scaled
production confirmed characteristic peaks of TCDMDA (C5H7
+
m/z = 67.05) and BA (C4H9+ m/z = 57.07) (Figure S7, Support-
ing Information). In addition, atomic force microscopy revealed
nanoscale topography in both deformation and modulus images
(Figure 3a,b). This indicated that nanoscale phase separation of
the monomers occurred before polymerization resulting in the
equivalent of a blend of polyBA (minor component, 30% v/v as
≈50 nm islands) in a continuous phase of polyTCDMDA (major
component, 70% v/v), rather than an uniform surface that would
be representative of a co-polymer. Hence, D:Q will be referred to
here as poly(TCDMDA-blend-BA).
To evaluate whether poly(TCDMDA-blend-BA) could support
hPSC attachment, proliferation, and expansion across serial pas-
sages, we evaluated the performance of ReBl-PAT, and two other
lines (AT1,[31] an in-house hiPSC line; HUES-7,[34] a human
embryonic stem cell (hESC) line from Harvard University). At
scale-up, we demonstrated that all three hPSC lines cultured on
poly(TCDMDA-blend-BA) could readily attach and proliferate,
reaching confluency every 72 h across 8 serial passages. hPSCs
showed a similar morphology to those growing on Matrigel (serv-
ing as a positive control) (Figure 3c). Whilst population doubling
time on poly(TCDMDA-blend-BA) (Figure 3d; AT1: 40 h ± 16 h,
HUES7: 40 h ± 13 h) was slower than Matrigel (AT1: 24 h ± 7
h, HUES7: 26 h ± 5 h) and laminin 521 (≈24 h) it was compa-
rable to commonly used ECM vitronectin (36 h) and previously
reported polymers for hPSC culture.[29,35] The hPSC lines also
retained stable karyotypes (46, XY for HUES7; 46, XY for ReBl-
PAT; 46, XX for AT1; Figure S8 and methods Supporting Infor-
mation) and maintained pluripotent marker expression of OCT4,
NANOG, SOX2, TRA181, and SSEA4 confirmed by flow cytom-
etry (Figure S9a, Supporting Information), quantitative real-time
PCR (Figure S9b, Supporting Information) and immunostaining
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(Figure S9c, Supporting Information, >80%) after 5 serial pas-
sages.
We and others have shown that protein adsorption to poly-
mer substrates from culture media is a critical step for mediat-
ing initial cell attachment.[21,36,37] We therefore next evaluated ad-
sorption of proteins from E8 culture medium on poly(TCDMDA-
blend-BA) by liquid extraction surface analysis-tandem mass
spectrometry (LESA-MS/MS).[38] Adsorption of medium-derived
proteins to the polymer interface was assessed in the absence
of cells for an optimized time of 1 h.[27,39–41] Followed by a rins-
ing procedure designed to retain species bound to the surface for
analysis by surface sampling (Figure 3e, see Supporting Informa-
tion for methods). Whilst minimal in its formulation, E8 includes
key pluripotency-maintaining factors: basic fibroblast growth fac-
tor (FGF2) and transforming growth factor beta 1 (TGF𝛽1); as
well as insulin and transferrin, which are required for hPSC at-
tachment and survival.[1]
The amount of each protein adsorbed by the polymer
poly(TCDMDA-blend-BA) capable of supporting attachment for
>72 h was compared to low and high attachment polymers
from the short-term 24 h attachment experiments. These are
denoted as monomers Q and P in Figures 1c and 2, polyBA
and polyTHFuA, respectively in Figure 3e. Of the four pro-
teins detected, significantly higher TGF𝛽1 adsorption was ob-
served on poly(TCDMDA-blend-BA) (p < 0.05) compared to poly-
mers which only supported attachment for 24 h. Since TGF𝛽1
is an important factor for maintaining hPSC pluripotency,[1]
it is likely that TGF𝛽 adsorption contributes to the success of
poly(TCDMDA-blend-BA) in long-term maintenance of hPSCs
in their undifferentiated state.
By 24 h, active cell adhesion was evident by cells altering
their morphology from round to flattened and spread-out cell
body by re-organization of the cytoskeleton driven by integrin-
mediated attachment, which subsequently promoted key hPSC
migration and proliferation signaling pathways.[42,43] At this
time point, we explored integrin-based mechanisms mediat-
ing active hPSC attachment on the poly(TCDMDA-blend-BA)
surface; antibodies and RGD (arginine-glycine-aspartate)-based
peptides were used to block integrins known to be highly ex-
pressed on the hPSC surface (Figure 3f; see Table S4, Sup-
porting Information for details).[44,45] Antibody-mediated block-
ing of vitronectin-binding 𝛼v𝛽3 (AT1, p < 0.01) and 𝛼v𝛽5 (p <
0.0001) integrins, the Matrigel -binding 𝛽1 integrin, as well as
RGD-peptides binding 𝛼v𝛽3 c(RGDfV), (p < 0.0001) and 𝛼v𝛽5
c(RGDfC) (p< 0.0001), significantly attenuated hPSC attachment
to poly(TCDMDA-blend-BA).[46–49] Expression of key integrins
(𝛼v, 𝛼5, 𝛽1, 𝛽4, and 𝛽5) was also confirmed through western blot-
ting (Figure S10a,b, Supporting Information). Integrin-mediated
hPSC attachment to synthetic polymer substrates including
poly(HPhMA-co-HEMA), notably of 𝛽1 and 𝛼v integrins, has been
previously reported.[17,21] These data suggest that 𝛼v𝛽3 and 𝛼v𝛽5
heterodimers play an important role for mediating hPSC attach-
ment to poly(TCDMDA-blend-BA), however, integrins are likely
to interact in a complex manner and therefore can form a num-
ber of different homo- or hetero- dimers. We can also infer that
the identified integrins which were mainly vitronectin binding
are likely to influence subsequent hPSC signaling when the cell
cytoskeleton is re-organized for stable cell adhesion for growth
expansion.
Intracellular signaling profiling of hPSCs cultured on
poly(TCDMDA-blend-BA) confirmed maintenance of stem
cell integrity. We now wished to explore the impact of these
interactions on molecular signaling pathways. A phospho-kinase
array kit (R&D) containing a panel of critical markers was used
to assess intracellular signaling events in two independent hPSC
lines (AT-1, HUES7) (Figure 3g).
Expression profiles for several kinases appeared to be cell
line specific. However kinases: c-Jun (S63), EGFR (epider-
mal growth factor receptor, Y1086) and PYK2 (tyrosine ki-
nase encoded by PTK2B, Y402) were differentially phospho-
rylated on poly(TCDMDA-blend-BA) compared to Matrigel in
both hPSC lines (Figure 3g). These kinases activate impor-
tant downstream hPSC proliferation pathways (including phos-
phoinositide 3-kinase/AKT, c-Jun, extracellular-signal-regulated
kinase/mitogen-activated protein kinases), most likely initi-
ated by integrin engagement (including 𝛼v, 𝛽1, and 𝛽3)
based on the integrin-interface characterization experiments
on poly(TCDMDA-blend-BA) (Figure 3c; Figure S10, Support-
ing Information).[50–52] Alternatively, adsorbed E8 factors, all
four of which were confirmed for poly(TCDMDA-blend-BA),
can promote hPSC signaling pathways by activating important
growth factor receptors (e.g. insulin-like growth factor receptor,
EGFR, fibroblast growth factor receptor, and transferrin recep-
tor) for hPSC signaling (proposed mechanism summarized in
Figure 3h).
In addition to maintaining hPSC attachment and pluripotent
signaling, the value of these cells for maintaining their differenti-
ation capacity to multiple lineages is of significant use in biomed-
ical and regenerative medicine applications. Therefore, after se-
rial passaging on poly(TCDMDA-blend-BA), directed differenti-
ation of hPSCs toward the three germ layers was performed.[11]
Definitive endoderm SOX17 and FOXA2 positive cells were
achieved after two days of WNT pathway activation with the GSK-
3 inhibitor CHIR99021 (Figure S11a, Supporting Information).
hPSC differentiation to SOX1 and PAX6 positive neural progeni-
tors of the ectoderm lineage was achieved with modulators of the
TGF-𝛽 superfamily (dual SMAD inhibitors dorsomorphin-1 and
SB431542) and WNT (XAV939) pathways (Figure S11b, Support-
ing Information). Functional contractile cardiomyocytes (meso-
derm) cells were formed using modulators of the TGF-𝛽 (activin
A and BMP4) and WNT (KY02111 and XAV393) pathways for 8–
12 days (Figure S11c, Supporting Information). Thus, achieving
multi-lineage differentiation, confirmed that stem cell integrity
was retained after serial passaging on poly(TCDMDA-blend-BA).
In summary, a high throughput combinatorial materials dis-
covery approach identified poly(TCDMDA-blend-BA) for long-
term hPSC culture in commercial defined E8 medium, with-
out the need for addition of xenogenic factors or attachment-
mediating proteins from culture medium. This simplified
system has advanced our understanding of the factors at the bio-
interface between media and polymer controlling stem cell re-
sponse. Protein adsorption of chemically defined E8 medium
was compared between different polymers using mass spec-
trometry methods. Together with cell-based assays, which inves-
tigated cell-polymer interactions, this enabled us to report on
mechanisms for cell adhesion and intracellular signaling which
corroborated well with our previous work e.g. poly(HPhMA-co-
HEMA) and other culture systems used routinely within the
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field.[1,5–7,9,17,21,33,39,46,49] This material constitutes a break-through
for the application of hPSCs, addressing current limitations of
scalability and production costs which could be reduced by ≈350
fold; costing ≈$0.0003 per well in a 96-well plate (factoring in a
10% saving from bulk orders based on BA # 234923) compared
to ≈$0.1 per well in a 96 well plate for current gold standard sub-
strates including Matrigel (Corning #11573620) and Synthemax
(Corning # CLS3535).
Experimental Section
Complete methodology of polymer synthesis, characterization, and cell-
based assays can be found in the Supporting Information.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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